{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:05:47Z","timestamp":1784549147032,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.carrev.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:31:30Z","timestamp":1784071890000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment effect of lipid-lowering strategy measured by intracoronary near-infrared spectroscopy (NIRS)-derived lipid core burden index (LCBI): A systematic review and meta-analysis"],"prefix":"10.1016","author":[{"given":"Aninka","family":"Saboe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sanz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio Sorolla","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector M.","family":"Garcia-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.carrev.2026.07.010_bb0005","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.jacc.2014.07.998","article-title":"Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease","volume":"64","author":"Oemrawsingh","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.carrev.2026.07.010_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehx247","article-title":"Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up","volume":"39","author":"Schuurman","year":"2017","journal-title":"Eur Heart J"},{"issue":"10278","key":"10.1016\/j.carrev.2026.07.010_bb0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","article-title":"Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study","volume":"397","author":"Erlinge","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.carrev.2026.07.010_bb0020","doi-asserted-by":"crossref","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000624","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.carrev.2026.07.010_bb0025","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.carrev.2026.07.010_bb0030","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.carrev.2026.07.010_bb0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.atherosclerosis.2008.05.014","article-title":"Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study","volume":"202","author":"Takarada","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.carrev.2026.07.010_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11883-020-00890-4","article-title":"Intra-coronary imaging for the evaluation of plaque modifications induced by drug therapies for secondary prevention","volume":"22","author":"Kilic","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"7","key":"10.1016\/j.carrev.2026.07.010_bb0045","first-page":"485","article-title":"Effects of lipid lowering therapies on vulnerable plaque features: an updated narrative review of the literature","volume":"25","author":"Biccir\u00e8","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.carrev.2026.07.010_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jacc.2013.03.058","article-title":"Changes in plaque lipid content after short-term intensive versus standard statin therapy","volume":"62","author":"Kini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2026.07.010_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2021.05.039","article-title":"Effect of atorvastatin (10 mg) and ezetimibe (10 mg) combination compared to atorvastatin (40 mg) alone on coronary atherosclerosis","volume":"154","author":"Oh","year":"2021","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.carrev.2026.07.010_bb0060","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.carrev.2026.07.010_bb0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ehjci\/jeab034","article-title":"Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study","volume":"23","author":"Ota","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.carrev.2026.07.010_bb0070","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4244\/EIJ-D-24-01065","article-title":"Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial","volume":"21","author":"Mensink","year":"2025","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2026.07.010_bb0075","series-title":"Changes in Plaque Lipid Content After 1 Year Intensive Versus Standard Statin Therapy: CITRUS Study (Serial Near-infrared spectroscopy Assessment of Change in Coronary Atherosclerotic Plaque). Presented at: TCT Congress","author":"Shin","year":"2023"},{"key":"10.1016\/j.carrev.2026.07.010_bb0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.carrev.2026.07.010_bb0085","first-page":"1","article-title":"Role of bailout gene-silencing therapy in plaque lipid reduction: intravascular imaging study","volume":"150","author":"Trusinskis","year":"2025","journal-title":"Cardiology"},{"issue":"6","key":"10.1016\/j.carrev.2026.07.010_bb0090","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jacc.2016.10.029","article-title":"Intracoronary imaging, cholesterol efflux, and transcriptomes after intensive statin treatment: the YELLOW II study","volume":"69","author":"Kini","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926002988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926002988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:20:02Z","timestamp":1784546402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838926002988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"alternative-id":["S1553838926002988"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2026.07.010","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment effect of lipid-lowering strategy measured by intracoronary near-infrared spectroscopy (NIRS)-derived lipid core burden index (LCBI): A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}